enGene Therapeutics (ENGN) AGM 2026 summary

Opening remarks and agenda

• Meeting called to order virtually, with operational rules for electronic voting and Q&A established.

• Only registered shareholders and proxy holders with control numbers could vote; beneficial shareholders required advance registration.

• Quorum confirmed as present, meeting declared properly constituted.

• Notice of meeting sent to all shareholders on May 19, 2026, in compliance with regulations.

Board and executive committee updates

• All board members and key management, including the independent auditor, were present and introduced.

Shareholder proposals

• Proposal 1: Election of four directors to serve until the 2029 AGM, with board recommending votes for management nominees.

• Proposal 2: Appointment of KPMG LLP as auditors until the next AGM, with board recommending approval.